Merck (MRK) Goodwill & Intangibles (2009 - 2026)
Merck's (MRK) quarterly Goodwill & Intangibles came in at $46.6 billion in Q2 2026, up 26.58% year-over-year from $36.8 billion in Q2 2025, and down 1.62% quarter-over-quarter from $47.3 billion in Q1 2026.
Analysis
Merck (MRK) Goodwill & Intangibles (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Goodwill & Intangibles for 18 consecutive years, with $46.6 billion the latest figure, recorded in Q2 2026.
- On a quarterly basis, Goodwill & Intangibles rose 26.58% year-over-year to $46.6 billion in Q2 2026; TTM through Jun 2026 was $46.6 billion, a 26.58% increase from a year earlier, with the FY2025 full-year figure at $48.3 billion, up 26.87% from the prior year.
- Goodwill & Intangibles was $46.6 billion for Q2 2026 at Merck, down from $47.3 billion in the prior quarter.
- Over five years, Goodwill & Intangibles peaked at $48.3 billion in Q4 2025 and troughed at $36.8 billion in Q2 2025.
- A 5-year average of $41.1 billion and a median of $40.6 billion in 2023 frame the typical range for Goodwill & Intangibles.
- Across the five-year window, Goodwill & Intangibles surged 34.51% in 2022 and retreated 7.26% in 2023, its largest moves.
- Over 5 years, Goodwill & Intangibles stood at $41.5 billion in 2022, then dropped by 5.46% to $39.2 billion in 2023, then retreated by 2.98% to $38.0 billion in 2024, then increased by 26.87% to $48.3 billion in 2025, then retreated by 3.52% to $46.6 billion in 2026.
- The last three Goodwill & Intangibles figures came in at $46.6 billion (Q2 2026), $47.3 billion (Q1 2026), and $48.3 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 46.56 Bn |
| Mar 31, 2026 | 47.33 Bn |
| Dec 31, 2025 | 48.26 Bn |
| Sep 30, 2025 | 36.90 Bn |
| Jun 30, 2025 | 36.78 Bn |
| Mar 31, 2025 | 37.44 Bn |
| Dec 31, 2024 | 38.04 Bn |
| Sep 30, 2024 | 38.71 Bn |
| Jun 30, 2024 | 38.15 Bn |
| Mar 31, 2024 | 38.75 Bn |
| Dec 31, 2023 | 39.21 Bn |
| Sep 30, 2023 | 40.38 Bn |
| Jun 30, 2023 | 40.86 Bn |
| Mar 31, 2023 | 41.07 Bn |
| Dec 31, 2022 | 41.47 Bn |
| Sep 30, 2022 | 42.53 Bn |
| Jun 30, 2022 | 43.71 Bn |
| Mar 31, 2022 | 44.28 Bn |
| Dec 31, 2021 | 44.20 Bn |
| Sep 30, 2021 | 32.25 Bn |